1/29/2014 8:53:13 AM
DUBLIN, Ireland, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the pricing of an underwritten public offering of 2,767,177 ordinary shares of Prothena at a price to the public of $26.00 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares are being sold by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). In addition, the Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 415,076 ordinary shares.
Help employers find you! Check out all the jobs and post your resume.
comments powered by